Toshiyuki Sakai

List of Publications by Year
in descending order

124 papers	5,685 citations	81900 39 h-index	82547 72 g-index
130 all docs	130 docs citations	130 times ranked	6861 citing authors

#	Article	IF	Citations
1	Î³-Glutamylcyclotransferase, a novel regulator of HIF-1Î± expression, triggers aerobic glycolysis. Cancer Gene Therapy, 2022, 29, 37-48.	4.6	7
2	DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Rasâ€“ERK pathway. Journal of Biochemistry, 2022, 171, 109-122.	1.7	5
3	Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells. Journal of Clinical Biochemistry and Nutrition, 2022, 70, 93-102.	1.4	1
4	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFRâ€T790M mutation in nonâ€small cell lung cancer cells. Cancer Medicine, 2022, 11, 944-955.	2.8	5
5	Oridonin inhibits SASP by blocking p38 and NF-Î°B pathways in senescent cells. Biochemical and Biophysical Research Communications, 2022, 590, 55-62.	2.1	10
6	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. Npj Precision Oncology, 2022, 6, 5.	5.4	13
7	The histone deacetylase inhibitor OBPâ€801 has inÂvitro/inÂvivo antiâ€neuroblastoma activity. Pediatrics International, 2022, 64, .	0.5	3
8	The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. International Journal of Molecular Sciences, 2022, 23, 2919.	4.1	2
9	â€œRB-reactivator screeningâ€•as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). , 2022, 236, 108234.		4
10	Artesunate inhibits intestinal tumorigenesis through inhibiting wnt signaling. Carcinogenesis, 2021, 42, 148-158.	2.8	4
11	Rabdosianone I, a Bitter Diterpene from an Oriental Herb, Suppresses Thymidylate Synthase Expression by Directly Binding to ANT2 and PHB2. Cancers, 2021, 13, 982.	3.7	4
12	Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 474-481.	8.1	47
13	Novel RAF/MEK inhibitor CH5126766/VSâ€6766 has efficacy in combination with eribulin for the treatment of tripleâ€negative breast cancer. Cancer Science, 2021, 112, 4166-4175.	3.9	6
14	The Combination of Cigarette Smoking and Alcohol Consumption Synergistically Increases Reactive Carbonyl Species in Human Male Plasma. International Journal of Molecular Sciences, 2021, 22, 9043.	4.1	2
15	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. Cancer Letters, 2021, 522, 119-128.	7.2	13
16	Tumor necrosis factorâ€related apoptosisâ€inducing ligand is a novel transcriptional target of runtâ€related transcription factorÂ1. International Journal of Oncology, 2021, 60, .	3.3	4
17	Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition. Cancers, 2020, 12, 1097.	3.7	9
18	Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS â€mutated ovarian cancer cells with high AXL expression. Cancer Science, 2020, 111, 2052-2061.	3.9	9

#	Article	IF	Citations
19	Very Long-Term Treatment with a Lactobacillus Probiotic Preparation, Lactobacillus Casei Strain Shirota, Suppresses Weight Loss in the Elderly. Nutrients, 2020, 12, 1599.	4.1	4
20	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2244-2256.	7.0	75
21	xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner. Cancers, 2020, 12, 827.	3.7	36
22	Histone deacetylase inhibitor OBPâ€‘801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1â€‘dependent apoptosis. International Journal of Oncology, 2020, 56, 848-856.	3.3	1
23	Cycloartenyl Ferulate and Î²-Sitosteryl Ferulate - Steryl Ferulates of Î³-Oryzanol - Suppress Intracellular Reactive Oxygen Species in Cell-based System. Journal of Oleo Science, 2019, 68, 765-768.	1.4	5
24	Sulforaphane enhances apoptosis induced by Lactobacillus pentosus strain Sâ€‘PT84 via the TNFÎ± pathway in human colon cancer cells. Oncology Letters, 2019, 18, 4253-4261.	1.8	8
25	Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients. Pharmacology, 2019, 104, 51-56.	2.2	7
26	Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma. Biochemical and Biophysical Research Communications, 2019, 512, 524-530.	2.1	12
27	Effect of physical fitness on colorectal tumor development in patients with familial adenomatous polyposis. Medicine (United States), 2019, 98, e17076.	1.0	6
28	Impact of Diarrhea after Drinking on Colorectal Tumor Risk: A Case Control Study. Asian Pacific Journal of Cancer Prevention, 2019, 20, 795-799.	1.2	1
29	FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells. Oncology Reports, 2018, 39, 627-632.	2.6	9
30	Design, synthesis and evaluation of Î³-turn mimetics as LSD1-selective inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 775-785.	3.0	17
31	Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells. Oncotarget, 2018, 9, 19597-19612.	1.8	16
32	Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2. Biochemical and Biophysical Research Communications, 2018, 505, 1203-1210.	2.1	10
33	In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma. Journal of Pediatric Surgery, 2018, 53, 2454-2459.	1.6	11
34	Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. Cancer Letters, 2018, 431, 182-189.	7.2	16
35	The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway. Breast Cancer Research and Treatment, 2018, 171, 43-52.	2.5	17
36	Higher enterococcus counts indicate a lower risk of colorectal adenomas: a prospective cohort study. Oncotarget, 2018, 9, 21459-21467.	1.8	3

#	Article	IF	Citations
37	Molecularâ€targeting therapies against quantitative abnormalities in gene expression with malignant tumors. Cancer Science, 2017, 108, 570-573.	3.9	11
38	Ribosomal protein S3 regulates XIAP expression independently of the NF-ÎºB pathway in breast cancer cells. Oncology Reports, 2017, 38, 3205-3210.	2.6	20
39	MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy. Journal of Pediatric Surgery, 2016, 51, 2074-2079.	1.6	27
40	Targeting Cancer with PCPAâ€Drug Conjugates: LSD1 Inhibitionâ€Triggered Release of 4â€Hydroxytamoxifen. Angewandte Chemie, 2016, 128, 16349-16352.	2.0	4
41	Targeting Cancer with PCPAâ€Drug Conjugates: LSD1 Inhibitionâ€Triggered Release of 4â€Hydroxytamoxifen. Angewandte Chemie - International Edition, 2016, 55, 16115-16118.	13.8	31
42	Age- and Gender-Specific Risk of Thyroid Cancer in Patients With Familial Adenomatous Polyposis. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4611-4617.	3.6	37
43	A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells. Molecular Cancer Therapeutics, 2016, 15, 2066-2075.	4.1	10
44	Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer. International Journal of Oncology, 2016, 48, 1297-1304.	3.3	4
45	MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells. Anticancer Research, 2016, 36, 4537-4544.	1.1	4
46	The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL. International Journal of Oncology, 2015, 46, 389-394.	3.3	27
47	Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells. Scientific Reports, 2015, 4, 6000.	3.3	14
48	Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells. PLoS ONE, 2015, 10, e0129851.	2.5	31
49	Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy, 2015, 48, 51-55.	1.8	28
50	PDK1 is a potential therapeutic target against angiosarcoma cells. Journal of Dermatological Science, 2015, 78, 44-50.	1.9	27
51	Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Molecular Oncology, 2015, 9, 309-322.	4.6	19
52	Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. PLoS ONE, 2015, 10, e0125779.	2.5	40
53	The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells. PLoS ONE, 2014, 9, e113217.	2.5	38
54	The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut, 2014, 63, 1755-1759.	12.1	107

#	Article	IF	Citations
55	CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1240-1246.	1.6	52
56	Xylarianaphthol-1, a novel dinaphthofuran derivative, activates p21 promoter in a p53-independent manner. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3389-3391.	2.2	25
57	Peroxisome proliferator-activated receptor Î³ ligand troglitazone and TRAIL synergistically induce apoptosis. Oncology Reports, 2014, 31, 947-954.	2.6	2
58	Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS. Gynecologic Oncology, 2013, 129, 425-432.	1.4	37
59	Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity. Cancer Research, 2013, 73, 4050-4060.	0.9	116
60	Perillyl alcohol causes G1 arrest through p15INK4b and p21WAF1/Cip1 induction. Oncology Reports, 2013, 29, 779-784.	2.6	23
61	Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2. PLoS ONE, 2013, 8, e55922.	2.5	54
62	The Flavonoid Apigenin Downregulates CDK1 by Directly Targeting Ribosomal Protein S9. PLoS ONE, 2013, 8, e73219.	2.5	33
63	Retinoblastoma geneâ€independent <scp>G</scp>₁ phase arrest by flavone, phosphatidylinositol 3â€kinase inhibitor, and histone deacetylase inhibitor. Cancer Science, 2012, 103, 2139-2143.	3.9	12
64	Aclarubicin enhances tumor necrosis factorâ€related apoptosisâ€inducing ligandâ€induced apoptosis through death receptor 5 upregulation. Cancer Science, 2012, 103, 282-287.	3.9	8
65	Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells. International Journal of Oncology, 2011, 38, 365-74.	3.3	9
66	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. International Journal of Oncology, 2011, 39, 23-31.	3.3	127
67	â€œCombination-oriented molecular-targeting preventionâ€of cancer: a model involving the combination of TRAIL and a DR5 inducer. Environmental Health and Preventive Medicine, 2010, 15, 203-210.	3.4	14
68	Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells. FEBS Letters, 2010, 584, 577-582.	2.8	31
69	Cucurbitacin B induces G₂ arrest and apoptosis via a reactive oxygen speciesâ€dependent mechanism in human colon adenocarcinoma SW480 cells. Molecular Nutrition and Food Research, 2010, 54, 559-565.	3.3	75
70	Cyclinâ€dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human Tâ€cell leukemia Jurkat cells. Cancer Science, 2010, 101, 728-734.	3.9	14
71	Cyclin-Dependent Kinase Inhibitors Enhance Sensitivity to Methotrexate In Human T-Cell Leukemia Jurkat Cells. Blood, 2010, 116, 3976-3976.	1.4	1
72	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Research, 2009, 11, R12.	5.0	65

#	Article	IF	Citations
73	Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environmental Health and Preventive Medicine, 2008, 13, 281-287.	3.4	38
74	Baicalein Overcomes Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells. Cancer Research, 2008, 68, 8918-8927.	0.9	107
75	Anti-Gout Agent Allopurinol Exerts Cytotoxicity to Human Hormone-Refractory Prostate Cancer Cells in Combination with Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand. Molecular Cancer Research, 2008, 6, 1852-1860.	3.4	38
76	YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. International Journal of Oncology, 2008, , .	3.3	8
77	YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. International Journal of Oncology, 2008, 32, 545-55.	3.3	13
78	ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signalâ€"regulated kinase pathway. Molecular Cancer Therapeutics, 2007, 6, 1579-1587.	4.1	29
79	Halocynthiaxanthin and Peridinin Sensitize Colon Cancer Cell Lines to Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand. Molecular Cancer Research, 2007, 5, 615-625.	3.4	44
80	Oct-1 is involved in the transcriptional repression of the p15INK4bgene. FEBS Letters, 2007, 581, 1087-1092.	2.8	20
81	Lipoxygenase inhibitors induce death receptor 5/TRAILâ€R2 expression and sensitize malignant tumor cells to TRAILâ€induced apoptosis. Cancer Science, 2007, 98, 1417-1423.	3.9	20
82	Sesamin, a lignan of sesame, downâ€regulates cyclin D1 protein expression in human tumor cells. Cancer Science, 2007, 98, 1447-1453.	3.9	117
83	Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor. Cancer Science, 2007, 98, 1809-1816.	3.9	50
84	15-Deoxy-Î"12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPARÎ³ and potentiates TRAIL-induced apoptosis. Molecular Cancer Therapeutics, 2006, 5, 1827-1835.	4.1	54
85	The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factorâ€"related apoptosis-inducing ligand. Molecular Cancer Therapeutics, 2006, 5, 945-951.	4.1	119
86	Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis, 2006, 27, 1768-1777.	2.8	55
87	Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene, 2005, 24, 7180-7189.	5.9	165
88	Artepillin C in Brazilian propolis induces G0/G1 arrest via stimulation of Cip1/p21 expression in human colon cancer cells. Molecular Carcinogenesis, 2005, 44, 293-299.	2.7	48
89	Quercetin induces gadd45 expression through a p53-independent pathway. Oncology Reports, 2005, 14, 1299.	2.6	7
90	Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. International Journal of Oncology, 2005, 26, 185.	3.3	41

#	Article	IF	Citations
91	A new cancer diagnostic system based on a CDK profiling technology. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 226-233.	3.8	23
92	The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochemical and Biophysical Research Communications, 2005, 333, 833-838.	2.1	84
93	Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene, 2004, 23, 5340-5349.	5.9	84
94	Activation of protein kinase C promotes human cancer cell growth through downregulation of p18INK4c. Oncogene, 2004, 23, 5409-5414.	5.9	24
95	Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene, 2004, 23, 6261-6271.	5.9	266
96	Promoter of TRAIL-R2 Gene. Vitamins and Hormones, 2004, 67, 35-49.	1.7	17
97	Trichostatin A activates p18INK4cgene: differential activation and cooperation with p19INK4dgene. FEBS Letters, 2004, 574, 171-175.	2.8	17
98	Indole-3-carbinol activates the cyclin-dependent kinase inhibitor p15INK4bgene. FEBS Letters, 2004, 576, 137-140.	2.8	26
99	Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. FEBS Letters, 2004, 577, 55-59.	2.8	44
100	Histone deacetylase inhibitors â€"Promising agents for â€˜gene-regulating chemopreventionâ€™ and â€˜molecular-targeting preventionâ€™ of cancerâ€". Environmental Health and Preventive Medicine, 2003, 8, 157-160.	3.4	8
101	p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene, 2003, 22, 7762-7773.	5.9	122
102	p15INK4bin HDAC inhibitor-induced growth arrest. FEBS Letters, 2003, 554, 347-350.	2.8	73
103	Molecular cloning and characterization of the human p19INK4dgene promoter. FEBS Letters, 2002, 517, 272-276.	2.8	9
104	Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene1. FEBS Letters, 2001, 507, 381-385.	2.8	118
105	Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene, 2000, 19, 5712-5719.	5.9	206
106	Butyrate as a model for â€œGeneâ€regulating chemoprevention and chemotherapyâ€• BioFactors, 2000, 12, 283-287.	5.4	54
107	Sp1 and NF-Y Synergistically Mediate the Effect of Vitamin D3 in the p27Kip1 Gene Promoter That Lacks Vitamin D Response Elements. Journal of Biological Chemistry, 1999, 274, 32309-32317.	3.4	150
108	Low frequency of oncogenic mutations in the core promoter region of the RB1 gene. Human Mutation, 1999, 13, 410-411.	2.5	6

#	Article	IF	Citations
109	The ubiquitous transcription factor NF-Y positively regulates the transcription of human p27Kip1through a CCAAT box located in the 5â€²-upstream region of the p27Kip1gene. FEBS Letters, 1999, 455, 281-285.	2.8	14
110	Cell Cycle-dependent Modulation of Promoter Activities ofRBandWAF1/Cip1Genes. Japanese Journal of Cancer Research, 1998, 89, 626-633.	1.7	2
111	Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts. FEBS Letters, 1998, 427, 203-208.	2.8	80
112	Differential activity of a variant form of the human Id-1 protein generated by alternative splicing. FEBS Letters, 1998, 436, 169-173.	2.8	13
113	Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells. FEBS Letters, 1998, 437, 61-64.	2.8	47
114	p53-Independent Activation of the gadd45 Promoter by Î”12-Prostaglandin J2. Biochemical and Biophysical Research Communications, 1998, 251, 648-652.	2.1	22
115	Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line. Journal of Biological Chemistry, 1997, 272, 22199-22206.	3.4	362
116	Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites. Biochemical and Biophysical Research Communications, 1997, 241, 142-150.	2.1	294
117	Molecular cloning and characterization of the human p27Kip1 gene promoter 1. FEBS Letters, 1997, 411, 1-6.	2.8	68
118	Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genetics and Cytogenetics, 1997, 98, 43-49.	1.0	126
119	ATF site of human RB gene promoter is a responsive element of myogenic differentiation. FEBS Letters, 1996, 397, 219-224.	2.8	14
120	Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature, 1991, 353, 83-86.	27.8	219
121	Flavonoids inhibit the expression of heat shock proteins.. Cell Structure and Function, 1990, 15, 393-401.	1.1	179
122	The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Letters, 1990, 260, 10-13.	2.8	269
123	N-mycsuppression and cell cycle arrest at G1phase by prostaglandins. FEBS Letters, 1990, 270, 15-18.	2.8	31
124	A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5. , 0, , .		1